Poster

MCLA-145 is a bispecific IgG1 antibody that inhibits PD-1/PD-L1 signaling while simultaneously activating CD137 signaling on T cells

Author

Paul Tacken

Condition

cancer

Drug target

CD137 (4-1BB) and PD-L1

Drug moa

CD137 activation and PD-L1 inhibition

Source url

s3://convoke-optic-posters/2024-05-10/P820-SITC-2020-Tacken-MCLA-145-poster-2.pdf

2 organizations

1 product

Product

Organization

Organization